FDA Approved: PROLEUKIN — Supplemental Application (Iovance Biotherapeutics, Inc)

View source ↗

Summary

FDA approved a supplemental application for PROLEUKIN (aldesleukin) filed by Iovance Biotherapeutics. The approval updates the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Proleukin (aldesleukin)

Snippet

SUPPL AP for PROLEUKIN (ALDESLEUKIN)